A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Phase 1
Completed
NCT06023095
| Condition | Overweight, Obesity |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 24 participants |
|---|
| Interventions | LY3502970 |
|---|
| Start date | Sep 21, 2023 |
|---|
| Completion date | Jul 29, 2024 |
|---|
| Results posted | Jul 17, 2026 |
|---|
Summary
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) · Participants
| LY3502970 (Cohort 1) | 10 Participants |
|---|
| LY3502970 (Cohort 2) | 8 Participants |
|---|
| Placebo | 3 Participants |
|---|
| LY3502970 (Cohort 1) | 0 Participants |
|---|
| LY3502970 (Cohort 2) | 0 Participants |
|---|
| Placebo | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.